帮我润色、优化、找出语法错误写成符合英文习惯的表达方式：Clinical factors such as CCR PCI pathological classification had been previously reported as prognostic factors of PMP in our clinical team The similar result in a large co

Clinical factors, including CCR, PCI, and pathological classification, have previously been reported as prognostic factors for PMP by our clinical team. A similar result in a large cohort study demonstrated that prior chemotherapy, histopathologic subtype, major postoperative complications, PCI, CCR, and not using HIPEC were independent predictors of poorer overall survival (OS) or progression-free survival (PFS). However, some studies on PMP have shown that only PCI is an independent predictor, rather than pathological classification. Gender and age may also be associated with PMP outcomes. Despite PMP having a favorable prognosis after undergoing CRS+HIPEC treatment, outcomes vary significantly. Generally, high-grade PMP has a worse impact on PFS or OS. However, accurately assessing the pathological grade of PMP can be challenging even for well-trained pathologists. Therefore, genomic dissection can provide a higher level of objectivity and overcome the limitations of organization-level assessment. We hypothesized that molecular aberrations could influence PMP outcomes. Thus, we evaluated the relationship between highly frequent mutations and progression-free survival or overall survival. Our findings suggest that TP53, SMAD4, MUC16 mutations, and a TMB>1 in PMP indicate a worse survival prognosis. Previous research on PMP has shown that aberrantly expressed p53 is associated with reduced survival. Similarly, in appendiceal mucinous neoplasms, TP53 mutation or p53 overexpression trends towards worse PFS and OS. In our cohort, we further validated the impact of TP53 status on survival. The effects of SMAD4 and MUC16 mutations on survival have not been reported previously. Numerous studies on PMP or appendiceal neoplasms have indicated a predominant role for KRAS and GNAS mutations. KRAS mutation has been proven to predict worse PFS following CRS and HIPEC in PMP. However, in our cohort, the status of KRAS mutations did not affect survival, and GNAS mutations were also not significantly associated with poor outcomes. Additionally, there were no significant differences found between groups in the survival analyses for tumor grade, PCI, CCR, and gender